Alfasigma

Executive Summary

Alfasigma USA, Inc. is a specialty biomedical company focused on personalized medicine through prescription medical foods designed to meet the distinct nutritional requirements of patients with specific medical conditions. Founded in 2015 and headquartered in Milan, Italy, the company leverages its expertise in small molecules and tailored nutritional interventions to address unmet needs in areas such as metabolic disorders, neurological conditions, and gastrointestinal diseases. By providing high-quality, clinically validated products, Alfasigma bridges the gap between traditional pharmaceuticals and dietary management, offering healthcare providers targeted solutions for patient care. The company's commitment to precision nutrition positions it uniquely in the growing market for personalized therapeutics, with potential for expansion into additional therapeutic indications.

Upcoming Catalysts (preview)

• Q4 2026Launch of new medical food product for pediatric metabolic disorders60% success
• Q3 2026Strategic partnership with major US hospital network to expand distribution70% success
• Q1 2027FDA approval for a novel prescription medical food targeting Alzheimer's-related nutritional deficiencies40% success